Updated September 2026Headline is the longer termMadeMed review
The advertised figure belongs to the six-month plan, and every line publishes the shorter term's rate beside it.
The verdict
MadeMed's advertised rate is attached to a commitment rather than to a month, and the seller prints the shorter term's rate beside it on every line. That is the disclosure worth crediting: a reader can see what the headline assumes without starting a checkout. What it cannot tell them is whether either rate survives a rising dose.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Injection
- From $239/mo
- Oral
- From $219/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- Not published by the provider
MadeMed sells compounded semaglutide and compounded tirzepatide in injected and oral forms, on plans rather than by the month. What distinguishes it from the many sellers that advertise a term rate is that it publishes both tiers on every line, so the discount for committing longer is visible rather than implied.
Who writes the prescription, and what do they see?
A prescription precedes dispensing and the service is remote. The pages describe plan structures rather than the clinician behind them, and the intake is not documented. A reader therefore learns a great deal about the commercial terms and very little about the clinical ones, which is the reverse of what a first-time buyer needs.
Pricing by term is a reasonable way to sell a treatment most people stay on for months, and MadeMed discloses it rather than burying it. The consequence a reader has to carry is that the advertised figure describes the deeper commitment, so setting it beside a monthly rate from another seller compares two different kinds of promise.
What happens when the dose goes up?
Nothing is published about what either tier costs as the dose climbs, which leaves the plan structure doing work it cannot do. A six-month commitment at $199 is only a six-month cost if the figure survives a titration schedule, and the pages do not say.
What the price includes
Each line carries two rates and MadeMed shows both, so the discount for committing longer is a visible number rather than an inference. The gap runs to forty dollars a month on semaglutide and thirty on tirzepatide. Billing happens in blocks either way, which means the commitment and the payment arrive together. Nothing states what either tier becomes at a higher dose, so neither is a half-year cost so much as a half-year rate.
What it claims, and what it cites
All four lines are compounded preparations rather than manufactured ones, which places them outside the FDA review an approved product passes before it is dispensed. The oral line adds vitamin B6 to the formulation. The approved product contains no such addition, and the pages do not say what it is there to do.
Where it holds up, and where it does not
- Strength: Each line shows both of its tiers
- Strength: The commitment behind the rate is named
- Strength: The additive in the oral is disclosed
- Limitation: The advertised rate needs six months
- Limitation: Quarterly costs $40 a month more
- Limitation: Billed in blocks rather than monthly
- Limitation: No dose behavior is published
What the evidence says about this kind of treatment
The assessment above is about MadeMed. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader ready to commit six months, which is the commitment the advertised figure assumes.
- Wrong for
- A reader who needs to leave without a term still running.
How MadeMed compares
| Seller | Who it suits | Go |
|---|---|---|
 BetterMe Rx | Readers who will confirm the sale is running and can commit three months | See BetterMe Rx → |
 Lttl | Readers who want every prepay rung visible and know which dose line they need | See Lttl → |
 June Health | Readers who want the escalation priced before enrolling rather than met in month three | See June Health → |
More GLP-1 telehealth sellers reviews: Breeze MedsCare Bare RxCoreAge RxStrut HealthSynergy RxActin
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- Can $199 be had on the shorter plan?
- No. It belongs to the six-month plan; the quarterly tier is the higher of the two, read August 2026.
- What is the real difference between the two plans?
- Forty dollars a month on semaglutide. The longer commitment is what buys it, and MadeMed publishes both tiers so the trade is visible.
- What is the B6 doing there?
- The oral line adds it to the formulation. The approved product contains none, and the pages neither price the addition nor explain its purpose.
- Is MadeMed expensive compared with other GLP-1 telehealth sellers?
- MadeMed publishes a starting figure of $219/mo. Across the 83 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $179, which puts MadeMed above the median. The other 5 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.